REGISTER
First China-Developed DPI Approved by FDA
Runsheng Pharmaceutical’s salmeterol/fluticasone dry powder inhaler has received FDA approval, becoming the first inhaled dry powder product independently developed by a Chinese drug company to reach the U.S. market. The complex generic closely matches the reference product in device structure and use.

On January 12 U.S. time, Runsheng Pharmaceutical announced that its salmeterol/fluticasone dry powder inhaler had formally received FDA approval for marketing. As a combination therapy consisting of a bronchodilator and an inhaled corticosteroid, the product is intended for regular treatment of reversible obstructive airway diseases such as asthma in adults and children, including asthma in adult and pediatric patients.

Runsheng Pharmaceutical said this is the first dry powder inhaler product approved by the FDA that was independently developed by a Chinese pharmaceutical company, marking a successful entry by China’s high-end complex formulations into mainstream international markets.

The reference product for salmeterol/fluticasone dry powder inhaler is GSK’s Advair Diskus, which became a benchmark medicine in the treatment of asthma and chronic obstructive pulmonary disease after its U.S. launch in 2000. Even though the inhaler device patent expired in 2016, technical barriers remained extremely high and the first globally equivalent generic was not approved by the FDA until 2019.

Runsheng’s product was developed in strict accordance with the FDA’s product-specific guidance for complex generics, ensuring product quality and compliance. At the same time, the internal structure and method of use of its inhalation device are almost identical to those of the reference product, which can improve patient adherence and facilitate a smooth switch for patients previously using the originator medicine.

Founded in October 2014, Runsheng Pharmaceutical is a company focused on high-end complex formulations built around inhaled drug delivery system platforms as its core technology. It has received investment from Juxin Investment, Yahua Healthcare, Boyi Xintian Capital, DT Capital, SDIC Venture Capital, Porton Pharma Solutions, CR Healthcare Fund, China Resources Sanjiu, CR Innovation Fund, CRCG-SGITIC, Industrial Guoxin, and Chongqing Changsheng Shenghe Fund, among others.

At present, Runsheng’s core pipeline covers therapies for asthma and chronic obstructive pulmonary disease, including salmeterol/fluticasone dry powder inhaler, fluticasone propionate dry powder inhaler, tiotropium bromide dry powder inhaler, and indacaterol/glycopyrronium bromide dry powder inhaler.

0
0
Loading